/

ࡱ>  bdfh  !"#$%&'()*+,-./0123456789:;?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`acdefghijklmnopqrstuvwxyz{|}~Root Entry F`,]`F)#^2Workbook__VBA_PROJECT_CUR"p$#^`F)#^VBA `F)#^`F)#^ \ptask Ba=-B0=830=T$8@"1Arial1Arial1Arial1Arial1Arial1Arial1Arial1Arial1Arial1Arial1 Arial1Arial1Arial1@ Arial1 Arial1"@  Arial Cyr1"  Arial Cyr1" Arial Cyr1"@ Arial Cyr1" Arial Cyr1" Arial Cyr1Arial/#,##0"@.";\-#,##0"@."9#,##0"@.";[Red]\-#,##0"@.";#,##0.00"@.";\-#,##0.00"@."E #,##0.00"@.";[Red]\-#,##0.00"@."k*3_-* #,##0"@."_-;\-* #,##0"@."_-;_-* "-""@."_-;_-@_-k)3_-* #,##0_@_._-;\-* #,##0_@_._-;_-* "-"_@_._-;_-@_-{,;_-* #,##0.00"@."_-;\-* #,##0.00"@."_-;_-* "-"??"@."_-;_-@_-{+;_-* #,##0.00_@_._-;\-* #,##0.00_@_._-;_-* "-"??_@_._-;_-@_- 0.000[$$-409]#,##0.000 #,##0.00"@." #,##0.000;[$-FC19]d\ mmmm\ yyyy\ "3."A[$-FC19]dd\ mmmm\ yyyy\ \3\.;@! ! ! ! ! ! ! ! ! ! ! ! ! ! !   ! ! ! ! ! <@ <   h< |< #x< x<  h< x< 0  (   h<  x;  $  |<  d<  #|<  |;  l; "|< "x< <@@ < @  8"@ @ j(9jJ219م>\`@09A&g!?5F?@54;>65=85 data;   ; T y /2y$bxul xnxul PNG IHDRXGTsRGB pHYs+xfIDATx^]`T^׸bRwB)R)܂BqwwY!dwBZ[^{̙3gqRQL3^F 1`ĀF b!#d0t:~4*Fq4F 1`Ā]!FHi͖7iлFb0&+l  2BcĀF `bklLjY1A((2*J8qHτG#0bC!NW7yh4C[;NuY/ԪnmؘF 1`T*XD*~cjaԼ=Z3BlĀF :jL#Ԅ#G+E v(pآCc 6G.lo^)i¸*0[щu2G4R&`q R*J1>K `$6U Sp$vnMÎFF pF\k'NĿ~Bia?'o}_VEW'}c3~ge?- |p b_)ȝףi >8pw2Y 8\w ?gXD$N}_OẆâxiY7A2s(2"*vkܙϿj~Q=IXdB($dD4FWUU&ew=3R jwK>h7jx6 j;erZO[fP6{6; JTT{$B强*B,G)kCZF~`4вFEG)ՂՁ#Xvܯr ҹ%@ufL؇:ZRkk-7 +=ũCQ^:S34&W gA _ySqK{G RkT= p ?F-iTB"aC5ۆjӧy[YL>Mctmi4%`r=_^mӉ8BD@䔄D(3E>;h '!|rg,ĺL)?r86@g$/z4,aAy~Z Ưd0WI$D%$ŃM>~tn&ŚV)mj$b?BA6vyG-4cRFlQ!5H*9hXP fO%Į4Sik6hgR\]fU*A9UM߸ aGZ"Ur c1%7Կ5Ă/TZhdR@"pd߃SnZ)'^nJ\.ɪJ`'V`Fa{tq #Whh"#I?Xhp'7g$87Tʑ!/þl5'.SX}tq}ʊەbQzM5h=)fanbjlj:ݫ]Y*v-)Ix~%], &iDVt ɤPbjeŢ%ŷ+˳jkZ@0m[O>V;cduhJqQVmm~!y[XE::9D^ `ZpzoUKʄrP߉Iti& (-=k_5D  0Q1/ "ˆ%78XDzOqtqG&n"ͫM_q_:ꅦ??r''84g}FVZ!qywz[~a>3'"ѽ'So?y'=CIϽae3"IJ:뇏kkY2RRW8N[o]{rŹ#hnq}Kv_,~sOGOU)g Z8"0N-kBV yJh慥vY.'b (dnE .EuG}?qJ&U*egT[ٍIE}}5.瑅ˉj_PpNTU@JS|=L=; ur8+Sݏt;r|Ƃ>_\8q֍g岫^Yj"&jMWV#Io]`t@q(< ,RHFs0O=|FH<ɷӉ$yXHD!Bu?qr*ۃ|؎P[#H.ԙn$7ctu}TXS'ڕ|}/]Y}--17heYJ""N%4M)+*UycҚSͶbw rvvu#&qxuS 6Aq&ηjBMTJ`XZ p-.*%Č^Φ`Lumumc'tySÓ7}7] w~i]sX1UF;3e.MKr/)l1FZl.|oN&bLfq]L!gM*LA,t"И5оlʡbQyZQ]8eNON FM۷mI,`S*Yl%K3A*a13xX!b16pG5?kո@#8M7uorΜ/xπ] yǀ3)4\ i ^*V` :[pˡ4W\2p/GgWU5pk`woK&M6ɕry׋;ss_;a/N ?MdFP ?2)&Cdik[0BVIt#L|yY\nRY]^\_ˆTj,᩵21Fcj痍WWlkR 9IJ;/?v}{YSo1'E߾qF Ň3U#}|gu r!T4rc!8~xtTzjͤfŀuxܷ/f.RYPcl9o+1S5&ٵ\8YY_{L>|Z&Q1$b//Z$&)ye~;nN;/ $R"6'FZUH./ ]ͬ7M ?-1Q:`ТI0q!zZQz98h5C.'J-'!M!8L$bj5\s^|WI/};"'.,[7͘ۅI8Aܡ;} bx}OF-3suo?<{9/ݾU˂s5M":'SK,9lAXL(/1?ؖmA0See,(sLLh̜M7J.gVҒ} ƒRn up#JxLFs1D`^/eJ qrpr&ܦZ l?$%${G] "\O'lgT.*LV\I=5o@/OZA⼰\3z\.i^P[!l]2ٌ0+z4]9 r}CH!jj䙚 O)++r AmD̅)lc %즦h49io]rԊҷOQJ TLn^ LcY:dP8ʒ.d6Pm&?Ɖ[o]r|,;`EK,HMN3 |&C7TvKGnjAWN#,t5Sf/^0?0"$BbvPL{&/u^ P" D9T掃|Ȧiܑ51j])Q^B>?p^H!1V & ^rz?s #XZ2Q +~W/]<:YGQѿopc?ޘXGg3~9H5"pmK0QEO [I[~-z۰?,+WLeqojzN`Iu@h)H,/EB!LyzF XUX-zx½k~oB67ͬjjÔo4Z~I`3:#y?N=@oygZ>mPuTў[)P+o5Nܲ~:Lk#biJ:%F!'^й;ĖĽ]\bNʸ/FH̍t,1_^s$*PrUpZ#l^:PHsi0,1eT`Df5b>8V"]6{ Q*]||1:O$g!O O7/龻&CblBk/V݌Z_h)LNlY„lgs|ڦ6h[ v$: gF /H޸{fڇؾ$;k➼'8H{svmu̓CƬRX7a^@f[> ?7R,mSOf9חnOj9d~rz-{px*nN`t8j!oeճ+|gX(p_+a"H.Cة0๽7is,zxs?9`c &V7 Tr k;ɪ^}8u{Z^&760l\oڼ`;,ڑsf\q4SOggtKtĖ ޭQ-%i0TRim뛸ȡ&Wdi5M^m!p6Z[sk`qCS$s/h@f7lai5PM.RT }r_Y}Y/;> =/dI!f,ܪ/΅^0Iw?# uֿ\TN-0ׅ^b@QL_))ẕӹP[m*C;:FHU25Ul1U*Xܩ"R4(/LbWo}wx!= iMxLkmG̐]H:jA? 0<|mPbg^5neCylO?[{%IaR6 sBb&IU]fpyV4.?D'YyhcHx' NH|1nCGZ 4оq\\C:{OzݢNuax`mDSM9_C\EK]䫯L⺄n .bIy671#:EIoS/xELkK-ؾAxQuQǑלׇm:5Wro+4 MY+ cH@aL?΁3ה0$v8=)7G$W '[CGY;b-Ǖ-H guyˇ RɐHF2 v@ CCgDg&b}Q*:` I&ߙ;D YVV(<-w QA6+]B,QRlꦭqdt~@xOp]AڿhWƎGVl)XTrjjeE[ș})+DD37FA}Ō0YJrA483(2etf /ڙtCt: =HtqcgZB$zVX}*k E ke6\4VkzdQ)|H'RFxNrkM`8/F9EAŽ$~0|C\pOVIzFiSIcNhZ;7yw$2'"[NA_T^ws oAj_/O{䒈~"Cl|b䒂ّ% .x&;m5bP>`Y RcJq'iO@ҵH;LY]tGvp}5H-wR*ߋoXoKt5=3mk6xXXz)'sv䀝sPeu*COpQ/2'e?⧙ ܑ(#;It\ wiCh>ԪûIJ? GW!d@'𼧐=TO -2V]f<ȈzZ* )ŸH:)K(U$NI_xLtfk_jRlQ!q5pmBwXkI@a^&s}L cEy8 MIbX)uιKfտv/N_{֢;8\ct|?QO(j&Qz 기`jmfpb3gב0[(]KXݕM/x{!- (vD2?9Zͫ@C/RӇ <:b }S\h)@[9xNߨɠ-ywܴ ;-lF`ia j+ w;EWTI%zh|)Rl%MAo~C% L&L&a L ?:{2n# <9u;yz`J* lkoҕB՝ZrN[ &? s Ujy ڜ/<̪ 3IQ:ByQN 3^%@=~Ucó&Z T'+sN^Z_O1aQl7޵|e_S-#<,鐨/Id)0 A([+K͸;gWB BU*4#98HB +79UCӇv\< 0&0l0X/;Tp4a){[xT =M#dȤ-d}Ǝ?+oM  0PH&$ڊ XwȀ_ù@5[]#9l{dBu67eLto7mYub(W)ޝ :{,-!/l^5Fz]RB ԕoH7jCF89|o. ̂۷x SM\V.01}[AKYTo~wHb62N*#<| OCI$ 6gN!6b0~9{X?*$1: GyT(7CBpB)~@lfU$T {D sˤ(8.\X'AjF԰ao7"Jsr7b`B6gel8,U55,΄"A1)ۑ^C, =R $̋ͿZ CXˤ 㯪g2!'8h~m$/d12PB~XؚdPc'jAgB0/mYXU$b;10b_մW1>A7&U9:LFV28^: Ĩ55s{y ښ[֊Y|[&vjm?5b|X$̐ڴđF\-G3>1IȻMJ*pZn $t7t #Ýҹa1hNDXȾ:NP6ή(~)}]Ye FL ߈$WCFyQsDpzdr>%nqyǩ~D16]i%ֲl_OUTS{eZ㨍WW>=hԒ^`GMqt5"|hkS'675oUGtD1y@"ݫjO Po;Y6/Ñt@➖gc6x.e]  V㿷whŢL؄99d ݛmg}<}߀M21?16UG?|oW}Wug`.VC( jjC<̷&Zu5߈j7";@7Bġa)挍ê(3  #JeIğmr<9djJD6LFE rV'zEBZē$=wK5-ܵI&M+oi Vj˕z+z/z;.e^:J2zә-8xJ[f!uG*+C|yBk.eO2jIwm ڂ[wNl+;K^r#7Ս_˓H&Q^(1Yc+)fF [OzUEzmU,W \nqSc\QAf,>>])x~0|bOgwҝzBByY2`vx8;ZH lΌZvHH&H+jR ܾ? p\SɯRYpPTՔe.;(HZSHüƠQ$WZ&;$,-ion'A$֑ե<1_,ir$iZh) ierށg-ut#J ~(OS!UᱜtG[e\,Wڛ yO R`nS؞ .G_;k3,808ԗn@/ %g %jzxyd!$~:U)]-mWlp]& ?_x*+]@3wKIL+-]CaO:nKwI<~;l߀^:+fwF )!TQ-@!8>H`3rEATR/~p$ں㿌OcwF 97 x9<",Q$0}E~eL&B8TE\(q& AS`lFhJ!5!Y7%; |pUYgů}5oߠDzB_(FARkX<`- L@"78ж'Pɪآ{//(PY9]]U9y$la&Y2i޽xFH9*- !Vck/1gS>q*na%~}tOfmuDUZ|>%!vvp88eD<{gSnq9x^D?5Xw0Jike)EDvO.U<4fHlgb3OԤ+Vy5_]:bpԯy~*u!fL,eYҒz9xH_oKz]VX/R^8588Ǔkk }s^8Bzp綋//M9+,B[yݮe BQ FLr?:SCZ{u\`jyb:?$\AoM󛤌K:%UhQ䃽?7wj3^ fҧi1Cn#նBCr2RNVG|ߦEByoĄ} W55ѽU{~5iK}ii~ |١{m,zNΗ>yHby`XtqVѹYOxl[_J'R#:ꌲXrYi8,&'t&R@ՓZUιi55-`|y|LzM5)t 2%Ĝ~27Ub-Xֹ'УsXs:oOeJ Ͼz?hɓ wGhc׸+ˎ{q) II#ge9u"g"_L5ʶ>j!ٺZJr6LklO,Zq䱥.25hH戌H9bQ;+IcqPsr{u(y--Q-1㑚!:egf|;FU{%ʠ EO{'SH扂m+}>@ iT6(&Ǘ9KG Ac|p 990R5E&q2š,-+ް&&TYrh4VfnXTO'R1{;USSZX|[@!`[|D(l][RsxnV6$߽ +HOKy9_](MI\d?}N% I=s9_?[Sd?^w6JDlo-Lhv&f?>|`ۭquP>QBKi qtfU%?tY(a-H:~>7)(Ǡ}6;Ѱ(WEO{|:#MHS7 6i=,FU)/D:[I!S)F[i\+KELna_0,ph"pl*3.1G˷|w߼ &\\O:q%UȤ,DRB5` #exyU5_h:/q#̚2!9u0a6&jRQRQNP݂ HW sЦ5$"62.N`!i_%]ܫDQl ]d;1n{rɜ'imHz7N,),pXPV:i~QbGbqQ՟uSUNeQ{6gE:/R.jJX 6Z1j{) Ҝ9Òez] FbMr P` :!Gq?9|^eRXK7"tn(` N28E3" -  B01 ?/> N21" -  B01 ?/> N21E3" # -"# N50" !" B01 ?/> 250 N40 !>B5:A >AA8O, !>B5:A/Pliva" !, D; 200E8<8:" $" 0<? 0,2% 1 5@>2L5" % 203.B01 500<3 N10" % B01 250<3 N20!" ! :0?A 300<3 N50 Troyan'" ! #"   35;L 2% 403 Sopharma!" ! #" ' :0?A 300<3 N30" !! 35;L 303 BC10"  !! 50<3 B01 N302AB@8O, Lannacher"  !! 100<3 B01 N30)"  3;.:0?;8 D;-:0?. 0,5% 10<; Rom C<K=8O, Rompharm C.O."" #!(%  "!)B01 50A;5@>4>2.N2 @.S (156) 0104&" #!. 4>@>4>2K5 N4 @.L (156) 0111'" #!. 4>@>4>2K5 N5 @.XL (156) 0111%" #!. 4>@>4>2K5 N1 @.XS (156) 0113%" #!. 4>@>4>2K5 N1 @.XS (15;) 0113$" #!. 4>@>4>2K5 N2 @.S (156) 0113$" #!. 4>@>4>2K5 N3 @.M (156) 0113$" #!. 4>@>4>2K5 N4 @.L (156) 0113%" #!. 4>@>4>2K5 N5 @.XL (156) 0113&" #!. 4>@>4>2K5 N6 @.XXL (156) 0113'" #!. " 4>@>4.A 45:.M;.N3 (15;) 0500'" #!. " 4>@>4.A 45:.M;.N4 (15;) 0500%" #!.  4>@>4>2K5 N2 @.S (15;) 9902%" #!.  4>@>4>2K5 N3 @.M (15;) 9902&" #!.  4>@>4>2K5 N5 @.XL (15;) 9902$" #!. " ?>A;5@>4>2K5 N5 (15;) 0106#" #!./ ?>A;5@>4>2K5 N2 (156) 0103#" #!./ ?>A;5@>4>2K5 N4 (15;) 0103#" #!./ ?>A;5@>4>2K5 N5 (156) 0103#" #!./ ?>A;5@>4>2K5 N5 (15;) 0103"# ! , :0?A N30"# ! $ A0H5 2,03 N10"# ! ', :0?A N30!"# ! ' >G8I5=85 D/? 23 N20"#!! .! A8@>? 118? 100<3/5<; 118<;"+" :0?A N15"+ :0?A 450AA8O, 2@>?0-8>D0@<  "+ :0?A 450<3 N84%"+  4/2=CB@.?@85<0 D; 100"#% "# 0<? 2,2<; N5"#% "# 0<? 2,2D0@<#," :0?A 20@#,"  -! 0<? 2A=+C:@5?+?>:@ 15A=>20 15:@KB85 15AAB.?>2@.=>3B59 15;I.=>3B.15=48F8>=5@ 4/:CB8:C;K 15=48F8>=5@ 4/=>3B59 15@@.=5>4=>@.=>3B.15<; Fren(#/ -,  4/:CB8:C;K 153C@.3B.15<; Fren$#/ -, AC?5@-ACH:0 15:@KB85 15<; Fren(#/ -, C2;.35;L-C:@5?8B.153B59 153B.15<; Fren(#/ -, CA8;8B5;L F25B0 15<; Frenchi(#/ -, MDD5:B :@.=>3B59 154=>< 1074>@>2;5=8O :CB8:C;K 10<;'# ! 70I.4/A2.<0=.10<; +  '# ! 70I8B=.4/A256.<0=8:N@0 10=4.=>3B.10<;+ #" 4@065 N50 #$#!  UPSA H8?.B01 500<3 N16$@0=F8O, UPSA Lab/Bristol&#!  UPSA H8?.B01 500;>:=O=:0) B01 N20 $$"#  $ 60% 20<; 0<? N10 A?0=8OA?0=8O, BerliMed"#  $ 76% 20<; 0<? N10 A?0=8O# ! D;-:0?. 25<;#  !" AC?? @5:B. 50<3 !10# !! :0?A 250<3 N10# !! :0?A 250<3 N50# !! :0?A 250?.3@0=C;K 103#! 3>?0B.B01 N20#!"- / .!#!!".+%.$" 25 20 40 20 20 20 20 40<3 N10 &$ !"  B01 10<3 N20 Terapia C<K=8O, Terapia $ !" B01 10<3 N10 Terapia($ !" B01 10AA8O, Terapia/:@8E8= %$$!"# 35;L 2,5% 303$!"# 35;L 2,5% 503$ $ 35;L 2,5% 303$  B01 50<3 N15$  B01 100<3 N15"$ :0?A 400<3+25 180 5<3 N30 IVAX$, B01 N20$ 4@065< N21$!" B01 2<3/10<3 N28$ B01 1<3 N50 )%$#" B01 250<3 N20 5;<54?@5?0@0BK$!" 35;L 303$!" &  :@5< 1% 23*$!" &  :@5<$.,! :0?A 150@.@-@0 0;8=0 A0H5 N8 Bris!$ ! ?0: N8 (1/A0E0@0) Bristol"$ ! ?0: N8 (A A0E0@><) Bristol'$  " ?0AB8;.652.503 $-#D08B0$  #  100<3 B01.652.N30 $  #  100<3/2<; 2/< 0? D; 100 0,4<3 N14($!"  B.?>7.0406-01 N1$," #-!" B01 400<3 N50 $, 35;L 0,5% 353 5@<0=8O5@<0=8O, C.P.M.Contract Pharma$ <07L 203 5@<0=8O5@ 5<3 N30 $! "  B01 200<3 N50 * $! "  B01 400<3 N50 *$"  #(+ N2 50AA8O, 50;LH0, Herbapol$"''+ B01 N10$"''+ B01 N50$"''+ B01 N10%$"!' #(+ 4/27@ N2 $8B>AA8O, $8B><548F8=0*$ !." B01 125<3 N20 Astellas 845@;0=4K, Astellas Pharma*$ !." B01 250<3 N20 Astellas *$ !." B01 500<3 N20 Astellas ($! !." B01 125<3 N20 Astellas($! !." B01 250<3 N20 Astellas($! !." B01 500<3 N20 Astellas$- B01 N100 Mucos5@<0=8O, Mucos Emulsions GmbH$- B01 N200 Mucos$  $ " ?0: N30$# :0?A 150B5:A*$#!"- :0?A 20@0=040, Apotex/5:B>@($#!" :0?A 10@/Nu-Pharm0=040, 5:B>@/Nu-Pharm($#!" :0?A 10@/Nu-Pharm >AA8O, 5:B>@/Nu-Pharm$#&  35;L 153$#&  <07L 153$.!"" 0,2% 50<; D; N1%$.!"" 150<3 :0?A N1 $-5:A@54AB20$$.!"" 50<3 :0?A N7 $-5:A@54AB20$  B01 5<3 N28$#! :0?A N20$#! :0?A 0,4<3 N30 Zentiva$  B01 N28#$/ !" 1<3 N50 5;0@CAL *$/ !" 1<3 N50 ) *$  :0?A 50<3 N4 Cipla$  :0?A 150<3 N1 Cipla$  :0?A 150<3 N3 Cipla$   D; 50AA8O,  % $!$ D; ;8>D.4/8= 2,53 N5$  10000/1<; 0<? N105;L38O, Pfizer$  250@"$  500@$" B01 500AA8O, @18BA:89 %$$"  " <07L 153&$# & @-@ D; 10?0B:0$# & @-@ D; 10<; /$$$#  50AA8O, "N<5=A:89 %$$#  B01 50@8A>2$# & @-@ 0,067% 10<; /$$"$# ! 0<? 1% 2<; N10 !5 *$# ! B01 40<3 N50 Sopharma$# ! B01 40<A:$#"/  4/?CABKH:8 19578$#& " :@5< 153 @;0=48O% " @-@ 4/8=D 500<; N10%& :0?A 20<3 N28 %& :0?A 250<3 N6 Hemofarm%, B01 N50%& :0?A 500@#% @0AB2.G09 65;C4>G.A 4 <5A.2003(259F0@8O, Hipp/Domaco'% !...D; 0,05% 100<; 5B5@1&% ! "- A?@59 100AA8O, =8:A 4% $- (% $") <0A;.@-@ 2% 20 15 50<3 N30 Zentiva% B01 300? 100AA8O, ! /-:>D;>@%! 35;L 103% "-! :0?A 250<3 !50(% " !#,$" 0D.2/< 100<3N10% ! 35;L 5% 303 86D0@< !% ! B01 250<3 !60 86D0@D5 4/?>E.68@>A6.1503 10%(%#  . :><?;.?8B0=.=0 54=.N5(&! ".! H8?.B01 500<3 N10 Zentiva(&! ".! H8?.B01 500<3 N20 Zentiva$&!" - A 30@0< :@5< 153&, " 0<? N5&, " 0<? N100&, " <07L 503&, " B01 N50'&' 4/?CABKH:8 A ?@8I.A 0 <5A 19502&  # "#  0<? N100&  # "#  0<? N5$& " 0<? 2/2, 2/< 250<3/<; 4<; !5& # 10<3 B01 N50#&"  ! :0?;8 10<3/<; 20? 5<3/5<; 75 10<3 N20&$ D; 13 2/2, 2/< 5;<54"&$ D; 13 2/2,2/  >AA8O, > "&$<  D; 13 2/2,2/A8=B57 %&$  @5:B.AC?? 50<3 N10 86D0@<%&$  @5:B.AC?? 250<3 N10 86D0@<&$  @5:B.AC?? N10 86D0@<!&$"! D; 13 2/2,2/< (&"!)=48O, Aurobindo Pharma Ltd&$"! D; 13 2/2,2/+&$" ! D; 13 2/2,2/< Shijiaz (8=4.C?.)8B09, Shijiazhuang Co Ltd&-  4@065 N21& ! B01 400<3 N24& !#!/ 1253 $$&/ <07L 10=:0 10% 253 $$!&/  124<3 N150 &  B01 25<3 N50 Sopharma&  B01 20<3 N14&  0<? 100<3/10<; N5 KRKA!&  0<? 100<3/10@&  @-@ 4/8=D 0,2% 100 250<3 N10& " 3;.:0?;8 3<3/<; 5<;& " @-@ 4/8=D 200<3 100 250 500<3 N10!& $!& B01 250=&& $!& B01 500<3 N10 (&!)!& $!& B01 500='& $!& D; 100<; 200D0@;>=.459A.?/> 500;>=.459A.?/> 1000 500D0@<&' :@5<-10;L703 75@0-$0@<'' :@5<-10;L70< 4/B5;0 75@0-$0@<' "" 0,075D0@D0@<'  :0?;8 50AA8O, -:>;>38O ?8B0=8O '!"" - B01 N100 -'!"" !#  1,0AA8O, 25 8=88 $ #'!"" !#  3,0AD0@;>A:0=8O 50<; Dr.Theiss $($ A  ;545=FK 503 Dr.Theiss($ B01 N20 $0@4C:B ($/ !",/ ?0G:0 353 $8B>D0@D0@D0@4.?H5=8FK(69(6 ? 200? 220;>B0O 0?;O >AA8O, $0@ ( A8@>? 250? 250<?.U-100 29G 1<;&( & !.Micr.Fine+ U-40 1<; 29G !(!(, Becton Dickinson&( & !.Micr.Fine+ U-40 1<; 30G !(&( & !.Micr.Fine+ U-100 1<; 29G !(&( & !.Micr.Fine+ U-100 1<; 30G !(#( & !#+ U-100 120:8O, Chirana T.Ingecta!( &  . 2<; Chirana 0,6E25 ( &  . 2<?.&( &  . 2<?.0,6E30%( &  . 5<?. 22G Vogt#( &  . 5<; Becton DickinsonA?0=8O, Becton Dickinson!( &  . 5<; Chirana 0,7E35&( &  . 5<?.0,7E30&( &  . 5<?.0,8E40&( &  . 5<?.0,7E40&( &  . 5<?.0,8E40#( &  .10<; Becton Dickinson!( &  .10<; Chirana 0,8E40 ( &  .10<?.&( &  .10<?.0,8E40%( &  .20<?. 21G Vogt#( &  .20<; Becton Dickinson!( &  .20<; Chirana 0,8E40 ( &  .20<?.&( &  .20<?.0,8E40((#" :@5<-10;L70< 4/ACAB.75@0-$0@(-" ;545=FK 503 2:.; Dr.Theiss-" $ " B01 N20 0@0D0@AA8O, 0@0D0@< &!-!" :0?;8 =070;. D;-:0? 10<;-" B01 5<3 N20-" B01 10<3 N20-" B01 20<3 N20 Gedeon-$ B01 250<3 N16-  H0<?C=L 150AA8O, ;51;KA5=8O 200@0-$0@<-!." 0,5<3 B01 N28-! :0?A 500<3 N60-#"  --" D; 50 250 500<3 N5$- ($) 0<? 0,1% 1<; N10'-!  "! D; 250<; N<8 8=4.C?."-!  "! D; 250AA8O, 5;835= $ *-!  "! D; 250<; 5;835= 8=4.C?.-!   # D; 25<; "25@L!-!  ! D; 100<; N<8!-!  ! D; 250<; N<8!-!   " D; 100<; 5;835=-!   " D; 250<; N<8!-!   " D; 250<; 5;835= -!  $" D; 250@ 20% 10< 0AA8O, ;8D5=/ 8:-$0@ 4 8<3 N6-! 0<? 1% 1<; N10 --! 3;.:0?;8 1% 5<; --  B01 5<3 N20 Agio *-  B01 5<3 N20 Hemofarm-  B01 5B5:A-  B01 10<3 N20 Agio *-  B01 10<3 N20 Hemofarm!-  B01 20<3 N20 Hemofarm *'-  B01 20B5:A/Jaka-80 *- B01 2,5<3 N20- B01 5<3 N20- B01 10<3 N20- B01 20<3 N20- H B01 10<3/25<3 N20 KRKA"- HL B01 10<3/12,5@- B01 2,5<3 N20 KRKA- B01 2,5@- B01 5<3 N20 KRKA- B01 5@- B01 10<3 N20 KRKA- B01 10@- B01 20<3 N20 KRKA- B01 20@-  B01 5<3 N20-  B01 10<3 N20-  B01 20<3 N20)-   :0?A N40 28B-<?;.4/<C6.!-! # B01 10<3 N30/2,5<3 N15'-! # $ " B01 20<3 N30/2,5 100? 2<3/<; 150 80 250<3 N20 "%$-! <07L BC10 303 86D0@<-!# :0?A 40<3 N25-!# D; 40<3/5<; 100<;'-!!&  0<? 250<3 5<; N5 Natterman5@@B5  :0?A 300<3 N30 Natter-!"$ B01 200<3 N30 8D8B5E-",$ :0?A 0,25<:3 N30-"" B01 250<3 N50 C30=A:-#" ! B01 50<:3 N100-#" ! B01 75<:3 N100-#" ! B01 100<:3 N100-#$ 150D0@< -#$ 150<3 N30 $-5:A@54AB20"-#$ 2,4% 102>A818@A:!-#$ 0<? 2,4% 5<; N10 !8=B57%-#$ # "# ! =07.A?@59 20<;-$ 10;L70< 253'-$$  @-@ 4/45B D; 3% 90<; Bristol&-$$  @5:B.AC?? 80<3 N10 Bristol&-$$  @5:B.AC?? 150<3 N10 Bristol&-$$  @5:B.AC?? 300<3 N10 Bristol$-$$  H8?.B01 500<3 N16 Bristol$-$$ +28B.! H8?.B01 N10 Bristol-%& --" B01 N12 Dr.Theiss-%& --" B01 N24 Dr.Theiss -%&/ - $  D; 50<;"-%&/ - :0?;8 50? 100<; 1/A0E.$.! !." 100 N21/  B01 ?/> N21 dimplex model silver (sp4) peg perego venezia funke dimplex model brayford 264-27-00 /